Sorafenib-induced Pemphigus Vulgaris
Indian Journal of Drugs in Dermatology · 2016
DOI: 10.4103/2455-3972.196172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Drugs in Dermatology, 2016. Verfasst von Ajay Deshpande. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanced primary hepatocellular carcinoma and radioactive iodine-resistant advanced thyroid carcinoma. Sorafenib is known to cause milder cutaneous side effects such as maculopapular rash and serious cutaneous drug reactions such as desquamation of the skin, hand-foot syndrome Stevens-Johnsons syndrome and toxic epidermal necrolysis. We report a histopathologicaly proved case of pemphigus vulgaris caused by sorafenib.
Zitieren
APA
Deshpande, A. (2016). Sorafenib-induced Pemphigus Vulgaris. Indian Journal of Drugs in Dermatology. https://doi.org/10.4103/2455-3972.196172
Vancouver
Deshpande A. Sorafenib-induced Pemphigus Vulgaris. Indian Journal of Drugs in Dermatology. 2016. doi:10.4103/2455-3972.196172
BibTeX
@article{Deshpande2016,
author = {Deshpande, Ajay},
title = {Sorafenib-induced Pemphigus Vulgaris},
journal = {Indian Journal of Drugs in Dermatology},
year = {2016},
doi = {10.4103/2455-3972.196172}
}
EUVIMED